Kas Granules India dividend on kindel?
Granules India on suurendanud dividendi juba 1 aastat.
Viimase 10 aasta jooksul on Granules India seda igal aastal 15,665 % suurendatud.
5-aastases perspektiivis tõusis dividendimakse 8,447 %.
Analaütikud prognoosivad käesolevaks majandusaastaks Dividenditõus kasvu 7,193%.
Granules India Aktienanalyse
Mis teeb Granules India?
Granules India Ltd is a registered company in Hyderabad, India, specializing in the manufacturing of pharmaceutical active ingredients and formulations, product development, biotechnology research, and diagnostics. The company was established in 1984 and has become one of the leading suppliers of pharmaceutical active ingredients.
The origins of Granules India Ltd began as a small company with only a few employees. In 1991, the company started production of Allantoin, a cosmetic active ingredient. Over the years, the company steadily grew and expanded its production capacities. In 1995, Granules India Ltd began manufacturing pharmaceutical active ingredients as part of its business.
In the late 90s, the company expanded into other countries to distribute its products worldwide. Today, the main markets for Granules India Ltd are India, North America, Europe, and Asia. The company also has distribution offices in the USA, Europe, and Asia.
Granules India Ltd has divided its business model into three main sectors:
1. Pharmaceutical Active Ingredients (APIs) - Granules India Ltd specializes in the manufacturing of pharmaceutical active ingredients used in drug production. The company produces a wide range of APIs, including Paracetamol, Ibuprofen, Metformin, and more.
2. Formulations - Granules India Ltd also produces various pharmaceutical formulations such as tablets, capsules, suspensions, and more. The company is able to develop and manufacture customized formulations according to customer requirements.
3. Biologics - In recent years, the company has also invested in biotechnology research, particularly in the development and manufacturing processes of biologics such as antibody drugs. The field of diagnostics is also covered.
Granules India Ltd has established a strong position as a manufacturer of pharmaceutical active ingredients in recent years. The company supplies many of the major pharmaceutical companies worldwide. It has six production facilities in India that manufacture pharmaceutical active ingredients and formulations. The company also supplies to other manufacturers to support their production processes.
In terms of products, Granules India Ltd offers a wide range of pharmaceutical active ingredients and formulations, all manufactured to the highest quality and in compliance with international standards. Some of the company's most well-known products are Paracetamol, Ibuprofen, Metformin, and Tramadol, used in pain management. The wide range of formulations includes tablets, capsules, suspensions, and more, used in various therapy areas such as cardiology, oncology, neurology, and infectious diseases.
Overall, Granules India Ltd has achieved a leading position in the market for pharmaceutical active ingredients and formulations. The company has invested in research and development in recent years to expand its product range and provide customized solutions. Granules India Ltd remains committed to meeting the high standards in the pharmaceutical industry and developing innovative products to meet the needs of its customers. Granules India on üks populaarsemaid ettevõtteid saidil Eulerpool.com.Aktsiasäästuplaanid pakuvad investoritele atraktiivset võimalust pikema aja jooksul vara koguda. Üheks peamiseks eeliseks on nn keskmise maksumuse efekt: investeerides regulaarselt kindla summa aktsiatesse või aktsiafondidesse, ostetakse automaatselt rohkem osakuid siis, kui hinnad on madalad, ja vähem, kui need on kõrged. See võib aja jooksul viia soodsama keskmise hinna per osakuni. Lisaks võimaldavad aktsiasäästuplaanid ka väikeinvestoritel pääseda ligi kallimatele aktsiatele, kuna nendega saab liituda juba väikeste summadega. Regulaarne investeerimine soodustab ka distsiplineeritud investeerimisstrateegiat ja aitab vältida emotsionaalsete otsuste, nagu impulsiivne ostmine või müümine. Peale selle saavad investorid osa aktsiate võimalikust väärtuse kasvust ning dividendide väljamaksetest, mida saab reinvesteerida, mis tugevdab intressiintressi efekti ning seeläbi investeeritud kapitali kasvu.